BlueRock Therapeutics to use Rune Labs’ Clinical Trial Platform to Better Characterize Parkinson’s Disease State in Cell Therapy Trials
Rune Labs, a precision neurology software and data platform company, today announced a partnership with BlueRock Therapeutics, a clinical-stage biopharmaceutical company and wholly-owned, independently operated subsidiary of Bayer AG. BlueRock will use StriveStudy, Rune Labs’ clinical trial platform featuring data collection and patient monitoring tools, to capture a holistic and precise picture of Parkinson’s disease activity and to better engage patients in the study.
The partnership is the first deployment of Rune Labs’ StriveStudy clinical trial platform, which enables more efficient studies of disease-modifying therapeutics to treat movement disorders. BlueRock will leverage Rune Labs’ Apple Watch-enabled data collection and remote patient monitoring tools in a non-interventional study, providing real-world, continuous capture of Parkinson’s symptom data using Rune Labs’ 510(k)-cleared technology.
Rune Labs’ StriveStudy platform will capture multimodal data from people with Parkinson’s to gain a better understanding of individual disease experience and build a dataset to characterize baseline symptom activity. BlueRock can leverage StriveStudy to monitor patient compliance by tracking how often they wear the Apple Watch in the study, as well as to improve the study experience for patients by streamlining data collection.
“Parkinson’s disease research has been limited in the past because there is no easy-to-measure, singular set of symptoms that each patient experiences – people with Parkinson’s have a wide array of symptoms that vary from person to person and frequently fluctuate. Historically, clinical researchers have used patient-reported questionnaires to assess symptoms, but they’re a subjective tool that fails to capture the dynamic nature of the disease,” said Rune Labs CEO Brian Pepin. “Together, BlueRock and Rune Labs will remotely collect longitudinal and objective data directly from patients to create a comprehensive image of Parkinson’s symptoms. By establishing a baseline symptom dataset, we will be able to fully capture the benefits of novel advanced therapies, increasing the efficiency of clinical trials in the future.”
This partnership paves the way for Rune Labs to streamline and enhance subsequent trials of BlueRock’s first-in-class stem cell-based therapy bemdaneprocel (BRT-DA01). BlueRock will be able to incorporate baseline and follow-up data collected via StriveStudy, including dyskinesias, into subsequent data analysis, thereby enabling a deeper understanding of BRT-DA01’s therapeutic benefit.
“Up until now, clinical trials have relied on patients with Parkinson’s disease to self-report their symptoms. Now, thanks to new technologies like Rune Labs’ platform, we have new tools to measure and assess disease progression,” said Seth Ettenberg, President and CEO of BlueRock Therapeutics. “We look forward to exploring with Rune Labs how objective and continuous measurements of disease progression can help us develop more effective therapies to treat Parkinson’s disease.”
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more